Orexin Receptor Modulators for Neurodegeneration

📖 Wiki Page

therapeutic1112 wordssynced 2026-04-02

Orexin Receptor Modulators for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Orexin Receptor Modulators for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Danavorexant</td>
<td>Idorsia</td>
</tr>
<tr>
<td class="label">Selivorexant</td>
<td>Idorsia</td>
</tr>
<tr>
<td class="label">Suvorexant</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Lemborexant</td>
<td>Eisai</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Orexin Dysfunction</td>
</tr>
<tr>
<td class="label">[Alzheimer's Disease](/diseases/alzheimers-disease)</td>
<td>Neuron loss, reduced orexin-A</td>
</tr>
<tr>
<td class="label">[Parkinson's Disease](/diseases/parkinsons-disease)</td>
<td>Aligned orexin secretion</td>
</tr>
<tr>
<td class="label">[CBS](/diseases/corticobasal-syndrome)</td>
<td>Sleep fragmentation</td>
</tr>
<tr>
<td class="label">[PSP](/diseases/progressive-supranuclear-gaze-palsy)</td>
<td>Circadian dysfunction</td>
</tr>
<tr>
<td class="label">[ALS](/diseases/amyotrophic-lateral-sclerosis)</td>
<td>Sleep disruption</td>
</tr>
<tr>
<td class="label">[FTD](/diseases/frontotemporal-dementia)</td>
<td>Sleep-wake cycle disruption</td>
</tr>
<tr>
<td class="label">[Huntington's Disease](/diseases/huntingtons)</td>
<td>Sleep architecture disruption</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Drug</td

...

Orexin Receptor Modulators for Neurodegeneration

Orexin neuropeptides (also known as hypocretins) play a critical role in regulating sleep-wake cycles, arousal, and autonomic function. The orexin system consists of two neuropeptides (orexin-A and orexin-B) and two G-protein-coupled receptors (OX1R/HCRTR1 and OX2R/HCRTR2). Dysfunction of the orexin system is implicated in multiple neurodegenerative diseases, making orexin receptor modulators a promising therapeutic approach.

Background

The Orexin System

The orexin system was discovered in 1998 by two independent groups[@de1998][@peyron1998]. Orexin-producing neurons are located primarily in the lateral hypothalamus and project widely throughout the brain, including to the [locus coeruleus](/cell-types/locus-coeruleus-noradrenergic), [tuberomammillary nucleus](/cell-types/tuberomammillary-nucleus-histaminergic-neurons), and [ventral tegmental area](/cell-types/ventral-tegmental-area-dopaminergic-neurons)[@sakurai2007][@jones2005].

Two orexin receptors mediate the effects of orexin neuropeptides:

OX1R (HCRTR1): Primarily involved in arousal and stress response
OX2R (HCRTR2): More involved in sleep-wake regulation and feeding behavior

Orexin Dysfunction in Neurodegeneration

Loss of orexin neurons is observed in [Alzheimer's disease](/diseases/alzheimers-disease)[@ferr2023] and [Parkinson's disease](/diseases/parkinsons-disease)[@videnovic2013]. This loss correlates with:

Sleep fragmentation and daytime sleepiness
Reduced glymphatic clearance of amyloid-beta and tau
Autonomic dysfunction
Cognitive decline

Dual Orexin Receptor Agonists

Dual orexin receptor agonists (DORAs) activate both OX1R and OX2R to compensate for orexin neuron loss. These compounds are being developed primarily by [Idorsia Pharmaceuticals](/companies/idorsia).

Danavorexant (ACT-541468)

Danavorexant is a dual orexin receptor antagonist (not agonist — see note below) developed by Idorsia for insomnia and sleep disorders in neurodegeneration.

Note: Danavorexant is classified as an orexin receptor antagonist, not agonist. The name can be confusing, but it works by blocking orexin receptors to promote sleep by reducing orexin-induced arousal, similar to suvorexant.

Clinical trials:

NCT07213349: Danavorexant for sleep disturbances in [Alzheimer's disease](/clinical-trials/daridorexant-ad-nct07213349) — Phase 2, recruiting

Selivorexant (ACT-462206)

Selivorexant is another dual orexin receptor antagonist from Idorsia being developed for sleep disorders. It has completed Phase 1 studies.

Comparison of Dual Orexin Receptor Antagonists

Dual Orexin Receptor Antagonists for Neurodegeneration

Suvorexant (Belsomra)

[Suvorexant](/therapeutics/suvorexant) was approved by the FDA in 2014 for insomnia disorder. It is a dual orexin receptor antagonist that promotes sleep by blocking orexin signaling.

Mechanism in Neurodegeneration:

Promotes sleep to enhance glymphatic clearance of amyloid-beta and tau[@kang2009]
Reduces orexin-mediated arousal that may exacerbate tau pathology[@feng2023]
Addresses orexin deficiency observed in AD[@ohno2020]

See the [Suvorexant therapeutic page](/therapeutics/suvorexant) for detailed clinical trials.

Lemborexant (Dayvigo)

[Lemborexant](/therapeutics/lemborexant-ad-nct06274528) is approved for insomnia and being studied in AD.

NCT06274528: Lemborexant for sleep disturbance in [Alzheimer's disease](/clinical-trials/lemborexant-ad-nct06274528) — Phase 2

See [Lemborexant AD clinical trial page](/clinical-trials/lemborexant-ad-nct06274528).

Therapeutic Rationale

Sleep-Wake Disturbances in AD

Over 50% of [Alzheimer's disease](/diseases/alzheimers-disease) patients experience sleep disturbances, including:

Sleep fragmentation
Sundowning (evening agitation)
Reduced REM sleep
Daytime sleepiness

Orexin receptor modulators address these issues by:

Promoting sleep continuity: Antagonists reduce orexin-mediated arousal during the night

Enhancing glymphatic clearance: Sleep promotes brain waste clearance

Reducing toxic protein accumulation: Both amyloid-beta and tau clearance are sleep-dependent

Sleep-Wake Disturbances in PD

[Parkinson's disease](/diseases/parkinsons-disease) patients commonly experience[@videnovic2013]:

REM sleep behavior disorder
Insomnia
Excessive daytime sleepiness
Sleep fragmentation

Orexin dysfunction contributes to these disorders, making orexin modulators a rational approach.

Cross-Disease Relevance

Orexin receptor modulators may benefit multiple neurodegenerative conditions:

Mechanism of Action

Mermaid diagram (expand to render)

Clinical Trials

Active Trials

Completed Trials

NCT04629547: Suvorexant STOP-AD — Completed
Phase 1 studies for Selivorexant — Completed

Future Directions

Novel Approaches

Peripherally-restricted DORAs: Minimize central nervous system side effects

OX2R-selective agonists: Target sleep-wake regulation without arousal effects

Combination therapy: Orexin modulators with [glymphatic-enhancing agents](/mechanisms/glymphatic-system)

Timing-based dosing: Align administration with circadian rhythm disruption patterns

Biomarkers

CSF orexin-A levels as a biomarker for orexin system dysfunction
Sleep polysomnography measures
Amyloid/tau PET imaging correlation

Side Effects and Safety

Common side effects of orexin receptor antagonists:

Excessive sleepiness
Sleep paralysis
Hypnagogic hallucinations
Complex sleep behaviors

In neurodegeneration patients, additional considerations:

Cognitive status monitoring
Fall risk assessment
Respiratory function in PD/ALS

Cross-Links

[Orexin Signaling in Neurodegeneration](/mechanisms/orexin-signaling-neurodegeneration)
[Sleep-Circadian Dysfunction in Alzheimer's](/mechanisms/sleep-circadian-dysfunction-alzheimers)
[Glymphatic System and Neurodegeneration](/mechanisms/glymphatic-system-neurodegeneration)

[Orexin Neurons](/cell-types/orexin-neurons-narcolepsy)
[Lateral Hypothalamus Orexin Neurons](/cell-types/lateral-hypothalamus-orexin-neurons)
[Tuberomammillary Nucleus Histaminergic Neurons](/cell-types/tuberomammillary-nucleus-histaminergic-neurons)

[Sleep Optimization Therapy](/therapeutics/sleep-optimization-therapy)
[Histamine H3 Receptor Antagonists](/therapeutics/histamine-h3-receptor-antagonists)
[Intranasal Therapy for Neurodegeneration](/therapeutics/intranasal-therapy-neurodegeneration)

[Daridorexant AD NCT07213349](/clinical-trials/daridorexant-ad-nct07213349)
[Lemborexant AD NCT06274528](/clinical-trials/lemborexant-ad-nct06274528)
[Suvorexant STOP-AD NCT04629547](/clinical-trials/suvorexant-stop-ad-nct04629547)

References

[Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness](https://doi.org/10.1038/nrn2092)

[Thompson, M. D., & Boozer, C. N. (2022). Orexin, sleep, and neurodegenerative disease](https://pubmed.ncbi.nlm.nih.gov/)

[Ferré, L. I., & Borbély, A. A. (2023). Orexin system in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/)

[de Lecea, L., et al. (1998). Proc Natl Acad Sci USA](https://doi.org/10.1073/pnas.95.1.322)

[Peyron, C., et al. (1998). Journal of Neuroscience](https://pubmed.ncbi.nlm.nih.gov/)

[Kang JE, et al. (2009). Amyloid-beta dynamics are regulated by orexin](https://doi.org/10.1016/j.neuroscience.2009.12.022)

[Ohno K, et al. (2020). Orexin deficiency and Alzheimer's disease](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)

[Feng Y, et al. (2023). Sleep disruption promotes tau pathology](https://doi.org/10.1093/brain/awad010)

[Videnovic, A., & Golombek, D. (2013). Circadian and sleep disorders in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/)

[Jones, B. E. (2005). Arousal systems of the brain](https://pubmed.ncbi.nlm.nih.gov/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄

📖 View canonical wiki page →

Orexin Receptor Modulators for Neurodegeneration

Orexin Receptor Modulators for Neurodegeneration

Orexin Receptor Modulators for Neurodegeneration

Background

The Orexin System

Orexin Dysfunction in Neurodegeneration

Dual Orexin Receptor Agonists

Danavorexant (ACT-541468)

Selivorexant (ACT-462206)

Comparison of Dual Orexin Receptor Antagonists

Dual Orexin Receptor Antagonists for Neurodegeneration

Suvorexant (Belsomra)

Lemborexant (Dayvigo)

Therapeutic Rationale

Sleep-Wake Disturbances in AD

Sleep-Wake Disturbances in PD

Cross-Disease Relevance

Mechanism of Action

Clinical Trials

Active Trials

Completed Trials

Future Directions

Novel Approaches

Biomarkers

Side Effects and Safety

Cross-Links

Related Mechanisms

Related Cell Types

Related Therapeutics

Other Sleep-Related Clinical Trials

References

Related Hypotheses